Haile, H., Upadhyayula, P. S., Karlovich, E., Sisti, M. B., Gill, B. J. A., & Donovan, L. E. (2025). Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report. Acta Neuropathologica Communications, 13(1). https://doi.org/10.1186/s40478-024-01894-w

Yeager, L. B., Li, C. Y., Bogolmony, D., Debelenko, L., & Marr, B. P. (2025). Vitreous Hemorrhage in Posterior Uveal Melanocytoma: Two Case Reports. Case Reports in Ophthalmological Medicine, 2025(1). Portico. https://doi.org/10.1155/crop/5126550

Dimitriou, F., Orloff, M. M., Koch Hein, E. C., Cheng, P. F., Hughes, I. F., Simeone, E., Montazeri, K., Grover, P., Mehmi, I., Gerard, C. L., Gaudy-Marqueste, C., Grob, J.-J., Michielin, O., Hamid, O., Long, G. V., Sullivan, R., Kapiteijn, E., Johnson, D. B., Ascierto, P. A., … Dummer, R. (2025). Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. European Journal of Cancer, 214, 115161. https://doi.org/10.1016/j.ejca.2024.115161

Yun, J. K., Ryu, Y. J., & Lee, Y. (2024). Case report: Squamous cell carcinoma in situ of the cornea without involvement of the limbus and conjunctiva. Frontiers in Medicine, 11. https://doi.org/10.3389/fmed.2024.1418228

Connelly, C. F., Desai, N., Cimic, A., Gonzalez, A. A., & Baskota, S. U. (2024). A six‐year comprehensive review of eye cytology cases received at a tertiary level hospital. Diagnostic Cytopathology, 52(9), 511–518. Portico. https://doi.org/10.1002/dc.25341

Gallitto, M., Pan, P. C., Chan, M. D., Milano, M. T., & Wang, T. J. C. (2024). The role of radiotherapy in immunotherapy strategies in the central nervous system. Neuro-Oncology, 26(Supplement_1), S66–S75. https://doi.org/10.1093/neuonc/noad184

Ventin, M., Cattaneo, G., Jia, J., Arya, S., Maggs, L., Sun, Y., Boland, G. M., Jenkins, R. W., Ksander, B. R., Haq, R., Wang, X., Ryeom, S., Ferrone, C. R., & Ferrone, S. (2023). 317 B7-H3-targeted CAR T cell with an inducible caspase 9 suicide gene effectively eradicates uveal melanoma liver metastases. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0317

Patel, S. P., Carvajal, R., Montazeri, K., Reddy, S., Lutzky, J., Khan, S. A., Chmielowski, B., Bhatia, S., Medina, T., Haymaker, C., Sheth, R., Kuban, J. D., Thornton, L., Wehrenberg-Klee, E., Novelli, P., Lucci, A., Sarli, V., Meas, S., Cox, B., … Davar, D. (2023). 1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial. Late-Breaking Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.1534

Orloff, M., Watkins, C., Carvajal, R. D., Shoushtari, A. N., Sacco, J. J., Schlaak, M., Gama, J., & Butler, M. O. (2023). 1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up. Annals of Oncology, 34, S678. https://doi.org/10.1016/j.annonc.2023.09.2263

Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., Luke, J. J., Mitchell, T. C., Mooradian, M. J., Rubin, K. M., Salama, A. K., Shirai, K., Taube, J. M., Tawbi, H. A., Tolley, J. K., … Sullivan, R. J. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for ImmunoTherapy of Cancer, 11(10), e006947. https://doi.org/10.1136/jitc-2023-006947

Mckean, M., Chmielowski, B., Butler, M. O., Carvajal, R., Rodon, J., Carlino, M., Kim, K. B., Wise-draper, T., Khan, S., Salama, A. K. S., Moser, J., Reeves, J., Wilner, K. D., Maurer, M., Abed, M., Mitchell, B., Beaupre, D., & Orloff, M. (2023). 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals of Oncology, 34, S651. https://doi.org/10.1016/j.annonc.2023.09.2215

Kim, A., Zhu, Y., Chen, D., Elmais, M., Athar, M., & Bickers, D. R. (2023). LB1763 Combinatorial BRD9 and SMO targeting synergistically suppress UV-induced BCC tumor burden in a murine model of Gorlin syndrome (GS). Journal of Investigative Dermatology, 143(9), B28. https://doi.org/10.1016/j.jid.2023.06.143

Bauer, S., Larkin, J., Hodi, F. S., Stephen, F., Kapiteijn, E. H. W., Schwartz, G. K., Calvo, E., Yerramilli-Rao, P., Piperno-Neumann, S., & Carvajal, R. D. (2023). A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975642

Jeong, J., Rand, G. M., Lee, J.-Y., & Kwon, J.-W. (2023). Novel limbal dermoid surgery for visual acuity and cosmesis improvement: A 7-year retrospective review. PLOS ONE, 18(6), e0286250. https://doi.org/10.1371/journal.pone.0286250

Vize, C. J., Kim, S. K., Matthews, T., Macsai, M., Merrell, R., Hsu, S., Kundu, M. G., Yoon, J., Kennedy, E., Pai, M., Bain, E., Lassman, A. B., & Moazami, G. (2023). A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. Ophthalmic Research, 1030–1043. Portico. https://doi.org/10.1159/000531142

Ambrosini, G., Natale, C. A., Musi, E., Garyantes, T., & Schwartz, G. K. (2023). The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells. Cancer Research Communications, 3(4), 540–547. https://doi.org/10.1158/2767-9764.crc-22-0399

Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., & Kapiteijn, E. (2023). A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. British Journal of Cancer, 128(6), 1040–1051. https://doi.org/10.1038/s41416-022-02133-6

Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., Johnson, D. B., Luke, J. J., Espinosa, E., Leyvraz, S., Collins, L., Goodall, H. M., Ranade, K., Holland, C., Abdullah, S. E., … Sato, T. (2022). Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine, 28(11), 2364–2373. https://doi.org/10.1038/s41591-022-02015-7

Khan, S., Patel, S. P., Shoushtari, A. N., Ambrosini, G., Cremers, S., Lee, S., Franks, L., Singh-Kandah, S., Hernandez, S., Sender, N., Vuolo, K., Nesson, A., Mundi, P., Izar, B., Schwartz, G. K., & Carvajal, R. D. (2022). Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975643

Wei, A. Z., Uriel, M., Porcu, A., Manos, M. P., Mercurio, A. C., Caplan, M. M., Hulse, L., Seedor, R. S., Holovatska, M., Francis, J., Khan, S. A., McDonnell, D. E., Bogomolny, D., Sato, T., Marr, B. P., Haq, R., Orloff, M., Shoushtari, A., & Carvajal, R. D. (2022). Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.961517

Sato, T., Ikeguchi, A. P., Nathan, P., Carvajal, R. D., Shoushtari, A. N., Gajewski, T. F., Hassel, J. C., Rioth, M., Leyvraz, S., Daniels, G. A., Hernandez-Aya, L., Johnson, D. B., Kim, K., Piulats Rodriguez, J. M., Cowey, C. L., Lockwood, S., Collins, L., Karakuzu, O., Sacco, J. J., & Butler, M. O. (2022). 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma. Annals of Oncology, 33, S934–S935. https://doi.org/10.1016/j.annonc.2022.07.969

Dimitriou, F., Hassel, J. C., Orloff, M., Hughes, I., Kapiteijn, E., Mehmi, I., Montazeri, K., Johnson, D. B., Grover, P., Gerard, C. L., Simeone, E., Gaudy Marqueste, C., Cheng, P., Long, G. V., Carvajal, R. D., & Dummer, R. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology, 33, S929. https://doi.org/10.1016/j.annonc.2022.07.958

Khan, S., Lutzky, J., Shoushtari, A. N., Jeter, J., Marr, B., Olencki, T. E., Cebulla, C. M., Abdel-Rahman, M., Harbour, J. W., Sender, N., Nesson, A., Singh-Kandah, S., Hernandez, S., King, J., Katari, M. S., Dimapanat, L., Izard, S., Ambrosini, G., Surriga, O., … Carvajal, R. D. (2022). Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.976837

Gordon, K. G., Carvajal, R. D., Graham, S. L., & Houghton, O. M. (2022). The reporting of uveal melanoma cases to the cancer registry in North Carolina. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.877599

Al-Dalahmah, O. A., Wang, L., Hsiao, S. J., Lin, C.-C., Mansukhani, M. M., Canoll, P., Bruce, J. N., & Zanazzi, G. (2022). Pineal region ganglioglioma: A neoplasm with a bimodal age distribution. Surgical Neurology International, 13, 245. https://doi.org/10.25259/sni_443_2022

Carvajal, R. D., Nathan, P., Sacco, J. J., Orloff, M., Hernandez-Aya, L. F., Yang, J., Luke, J. J., Butler, M. O., Stanhope, S., Collins, L., McAlpine, C., Holland, C., Abdullah, S. E., & Sato, T. (2022). Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 40(17), 1939–1948. https://doi.org/10.1200/jco.21.01805

Lin, W. V., Rand, G. M., Miller, M. L., Marr, B. P., & Suh, L. H. (2022). A case of sight threatening complications from topical 1% 5-fluorouracil in the treatment of ocular surface squamous neoplasia. American Journal of Ophthalmology Case Reports, 25, 101265. https://doi.org/10.1016/j.ajoc.2022.101265